+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Market Trajectory & Analytics

  • ID: 1244801
  • Report
  • April 2021
  • Region: Global
  • 201 Pages
  • Global Industry Analysts, Inc
1 of 2
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $23.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$23.8 Billion by 2027, growing at a CAGR of 5% over the period 2020-2027. Stimulant, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Stimulant segment is readjusted to a revised 6.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5 Billion, While China is Forecast to Grow at 4.7% CAGR

The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Select Competitors (Total 27 Featured):
  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • ADHD Therapeutics: A Primer
  • Recent Market Activity
  • ADHD Therapeutics Market Outlook
  • Factors Driving ADHD Therapeutics Market
  • Changes in Insurance Coverage
  • Addition of Formal Guidelines
  • Low Diagnosis Threshold
  • Advancements in Field of Medicine
  • Unmet Needs
  • Launch of Pipeline Drugs
  • Factors Inhibiting ADHD Therapeutics Market
  • Side Effects Related to Use of Stimulants to Treat ADHD
  • Under-diagnosis of ADHD Condition
  • Reduced Availability of Non-Stimulants in Certain Geographies
  • Competitive Landscape
  • Major ADHD Medications Available in the Market
  • ADHD Medications Approved by FDA
  • Patent Validity for Major ADHD Drugs
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • Alcobra Ltd. (Israel)
  • Amarantus Bioscience Holdings, Inc. (US)
  • Amedra Pharmaceuticals LLC (US)
  • Curemark, LLC. (US)
  • Eli Lilly and Company (US)
  • Intellipharmaceutics International, Inc. (US)
  • Janssen Global Services, LLC (US)
  • Mallinckrodt PLC (Ireland)
  • Mylan N.V. (The Netherlands)
  • Neos Therapeutics, Inc. (US)
  • Neurovance, Inc. (US)
  • Noven Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Supernus Pharmaceuticals, Inc. (US)
  • Tris Pharma, Inc. (US)
3. MARKET TRENDS & DRIVERS
  • Biological Psychiatry Gaining Ground
  • Social Media Drives Heightened Awareness
  • Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
  • Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
  • Strategic Alliances
4. GLOBAL MARKET PERSPECTIVE
  • III. MARKET ANALYSIS
  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • REST OF EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD
IV. COMPETITION
  • Total Companies Profiled: 27
Note: Product cover images may vary from those shown
Adroll
adroll